Cyclooxygenase-2 inhibition prevents renal toxicity but not hypertension during sunitinib treatment

被引:0
|
作者
van Dorst, Daan C. H. [1 ,2 ,6 ]
Colafella, Katrina M. Mirabito [3 ,4 ]
van Veghel, Richard [1 ]
Garrelds, Ingrid M. [1 ]
de Vries, Rene [1 ]
Mathijssen, Ron H. J. [2 ]
Danser, A. H. Jan [1 ]
Versmissen, Jorie [1 ,5 ]
机构
[1] Erasmus MC Univ Med Ctr, Dept Internal Med, Div Vasc Med & Pharmacol, Rotterdam, Netherlands
[2] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[3] Monash Univ, Biomed Discovery Inst, Cardiovasc Dis Program, Melbourne, Australia
[4] Monash Univ, Dept Physiol, Melbourne, Australia
[5] Erasmus MC Univ Med Ctr, Dept Hosp Pharm, Rotterdam, Netherlands
[6] Dept Internal Med, Div Pharmacol & Vasc Med, room EE-1424 Erasmus MC Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands
关键词
Cardio-oncology; Angiogenesis inhibitors; Hypertension; Renal toxicity; Cyclooxygenase-2; Prostanoids; BLOOD-PRESSURE; PROSTACYCLIN SYNTHESIS; ARACHIDONIC-ACID; CELECOXIB; COX-2; ACTIVATION; ILOPROST; MODEL;
D O I
10.1016/j.ejphar.2023.176199
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Anticancer angiogenesis inhibitors cause hypertension and renal injury. Previously we observed in rats that high-dose aspirin (capable of blocking cyclooxygenase (COX)-1 and-2) was superior to low-dose aspirin (blocking COX-1 only) to prevent these side-effects during treatment with the angiogenesis inhibitor sunitinib, suggesting a role for COX-2. High-dose aspirin additionally prevented the rise in COX-derived prostacyclin (PGI(2)). Therefore, we studied the preventive effects of selective COX-2 inhibition and the hypothesized contributing role of PGI(2) during angiogenesis inhibition.Methods: Male WKY rats received vehicle, sunitinib ((SU), 14 mg/kg/day) alone or combined with COX-2 inhibition (celecoxib, 10 mg/kg/day) or a PGI(2) analogue (iloprost, 100 mu g/kg/day) for 8 days (n = 8-9 per group). Mean arterial pressure (MAP) was measured via radiotelemetry, biochemical measurements were performed via ELISA and vascular function was assessed via wire myography.Results: SU increased MAP (17 +/- 1mmHg versus 3 +/- 1mmHg after vehicle on day 4, P < 0.002), which could not be significantly blunted by celecoxib (+12 +/- 3mmHg on day 4, P = 0.247), but was temporarily attenuated by iloprost (treatment days 1 + 2 only). Urinary PGI(2) (996 +/- 112 versus 51 +/- 11ng/24h after vehicle, P < 0.001), but not circulating PGI(2) increased during SU, which remained unaffected by celecoxib and iloprost. Celecoxib reduced sunitinib-induced albuminuria (0.36 +/- 0.05 versus 0.58 +/- 0.05mg/24h after SU, P = 0.005). Wire myography demonstrated increased vasoconstriction to endothelin-1 after SU (Emax P = 0.005 versus vehicle), which remained unaffected by celecoxib or iloprost.Conclusion: Selective COX-2 inhibition ameliorates albuminuria during angiogenesis inhibition with sunitinib, which most likely acts independently of PGI(2). To combat angiogenesis inhibitor-induced hypertension, dual rather than selective COX-1/2 blockade seems preferential.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Renal effects of chronic cyclooxygenase-2 inhibition changes with sodium intake
    Roig, F
    Llinas, MT
    Lopez, R
    Rodriguez, F
    Salazar, FJ
    HYPERTENSION, 2001, 38 (04) : 982 - 982
  • [22] Selective cyclooxygenase-2 inhibition: A target in cancer prevention and treatment
    Subongkot, S
    Frame, D
    Leslie, W
    Drajeeer, D
    PHARMACOTHERAPY, 2003, 23 (01): : 9 - 28
  • [23] Renal effects of cyclooxygenase-2 (COX-2) inhibition in fetal lambs
    Kajino, H
    Roman, C
    Clyman, RI
    PEDIATRIC RESEARCH, 2000, 47 (04) : 471A - 471A
  • [24] Chronic cyclooxygenase-2 inhibition prevents the worsening of hypertension and endothelial dysfunction induced by ouabain in resistance arteries of spontaneously hypertensive rats
    de Oliveira, Helane Tito
    Couto, Gisele Kruger
    Davel, Ana Paula
    Xavier, Fabiano Elias
    Rossoni, Luciana Venturini
    VASCULAR PHARMACOLOGY, 2021, 139
  • [25] Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats
    Bezerra, MM
    de Lima, V
    Alencar, VBM
    Vieira, IB
    Brito, GAC
    Ribeiro, RA
    Rocha, FAC
    JOURNAL OF PERIODONTOLOGY, 2000, 71 (06) : 1009 - 1014
  • [26] Colorectal cancer and inhibition of cyclooxygenase-2
    Geissler, M
    Mohr, L
    Blum, HE
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (23) : 1256 - 1258
  • [27] SELECTIVE-INHIBITION OF CYCLOOXYGENASE-2
    KLEIN, T
    NUSING, RM
    PFEILSCHIFTER, J
    ULLRICH, V
    BIOCHEMICAL PHARMACOLOGY, 1994, 48 (08) : 1605 - 1610
  • [28] Cyclooxygenase-2 inhibition and gastric cancer
    Jiang, XH
    Wong, BCY
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (27) : 2281 - 2288
  • [29] Cyclooxygenase-2 inhibition and cardiovascular events
    Pitt, B
    Pepine, C
    Willerson, JT
    CIRCULATION, 2002, 106 (02) : 167 - 169
  • [30] Pharmacology of cyclooxygenase-2 inhibition in the kidney
    Khan, KNM
    Paulson, SK
    Verburg, KM
    Lefkowith, JB
    Maziasz, TJ
    KIDNEY INTERNATIONAL, 2002, 61 (04) : 1210 - 1219